Immutep (IMMP) Assets Average (2012 - 2025)
Immutep's (IMMP) quarterly Assets Average came in at $98.6 million in Q4 2025, down 21.78% YoY from $126.0 million in Q4 2024, and down 10.28% on a QoQ basis from $109.9 million in Q2 2025.
Immutep (IMMP) Assets Average (2012 - 2025) Analysis & Trends
Immutep (IMMP) has 14 years of Assets Average data on file, last reported at $98.6 million in Q4 2025.
- Quarterly Assets Average fell 21.78% year-over-year to $98.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $98.6 million (down 21.78% YoY) and the FY2025 annual result came in at $116.7 million, up 0.86% from the prior year.
- Assets Average declined to $98.6 million in Q4 2025, from $109.9 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $126.0 million in Q4 2024 to a low of $59.5 million in Q2 2021.
- A 5-year average of $88.8 million and a median of $85.0 million in 2022 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2021 — Assets Average jumped 98.81% — and 2025, when it decreased 21.78%.
- Tracing IMMP's Assets Average over 5 years: stood at $75.4 million in 2021, then dropped by 13.96% to $64.8 million in 2022, then jumped by 38.12% to $89.6 million in 2023, then surged by 40.72% to $126.0 million in 2024, then declined by 21.78% to $98.6 million in 2025.
- The last three Assets Average figures came in at $98.6 million (Q4 2025), $109.9 million (Q2 2025), and $126.0 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 19.82 Bn |
| 10 | Immutep | 55.96 Mn | -9.12 Mn | - | 98.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 98.59 Mn |
| Jun 30, 2025 | 109.89 Mn |
| Dec 31, 2024 | 126.04 Mn |
| Jun 30, 2024 | 106.72 Mn |
| Dec 31, 2023 | 89.57 Mn |
| Jun 30, 2023 | 77.53 Mn |
| Dec 31, 2022 | 64.85 Mn |
| Jun 30, 2022 | 80.38 Mn |
| Dec 31, 2021 | 75.37 Mn |
| Jun 30, 2021 | 59.53 Mn |
| Dec 31, 2020 | 43.22 Mn |
| Jun 30, 2020 | 29.94 Mn |
| Dec 31, 2019 | 26.63 Mn |
| Jun 30, 2019 | 29.26 Mn |
| Dec 31, 2018 | 35.09 Mn |
| Jun 30, 2018 | 30.92 Mn |
| Jun 30, 2017 | 26.52 Mn |
| Mar 31, 2017 | 27.70 Mn |
| Dec 31, 2016 | 30.20 Mn |
| Jun 30, 2015 | 12.06 Mn |